Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02392351 · ClinicalTrials.gov registry record · NA
Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT02392351 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 51 participants.
The verdict
NCT02392351, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and ≤180 mmHg) shows acceptable performance at 8 weeks when compared to a masked procedure (renal angiogram).
Interventions
- DEVICE Renal Denervation (Vessix)
- DEVICE Renal Angiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-08-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02392351
The ClinicalTrials.gov registry entry for NCT02392351 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Renal Denervation (Vessix) is the first listed.
NCT02392351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02392351 about?
NCT02392351 is a clinical study titled "Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)". The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and ≤180 mmHg) shows acceptable performance at 8 weeks when compared to a m...
What is the current status of trial NCT02392351?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2015-04. Estimated completion is 2019-08-02.
What interventions are being tested in trial NCT02392351?
The interventions under investigation include: Renal Denervation (Vessix) (DEVICE), Renal Angiography (DEVICE).
Who is sponsoring clinical trial NCT02392351?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.